BioLineRx (BLRX) Reports FY 21 Net Loss of $27.1M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to BioLineRx (BLRX) Reports FY 21 Net Loss of $27.1M

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update

March 16, 2022 7:00 AM EDT

TEL AVIV, Israel, March 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

Significant events and achievements during the fourth quarter 2021 and subsequent period:

Commissioned a comprehensive third-party market assessment of the US stem cell mobilization market, which identified a commercial opportunity in the US of ~$360 million; Completed a successful... More